SEC and FDA Formalize Information-Sharing Agreement

The US Securities and Exchange Commission (SEC) and the US Food and Drug Administration (FDA) formalized an information-sharing framework on August 31, 2026. This agreement mandates that life science companies more rigorously consider securities laws. The formalization of this framework is expected to increase scrutiny on how these companies disclose information and conduct their operations.

The details

On August 31, 2026, the US Securities and Exchange Commission (SEC) and the US Food and Drug Administration (FDA) entered into a memorandum of understanding (MOU). This MOU establishes a formal framework for the sharing of information between the two federal agencies. The primary mechanism of this agreement is to facilitate a more robust exchange of data and insights between the SEC, which regulates securities markets, and the FDA, which oversees the safety and efficacy of medical products.

The direct impact of this ramped-up information sharing is that life science companies are now compelled to more rigorously consider securities laws. This means that disclosures made to investors, particularly those concerning product development, clinical trials, regulatory approvals, and potential risks, will be subject to a dual lens of scrutiny: both for compliance with FDA regulations and for adherence to SEC disclosure requirements regarding material information. The agreement aims to prevent situations where information provided to one agency might contradict or be inconsistent with disclosures made to the other, or where a company might selectively disclose information to investors without fully accounting for its regulatory status.

This formalization builds upon existing, informal cooperation between the agencies, elevating it to a structured and systematic process. The specific types of information to be shared, and the protocols for that sharing, are outlined within the MOU, though the full details were not publicly enumerated in the initial reports. However, the intent is clear: to ensure that investors receive accurate and complete information, particularly in an industry where regulatory milestones and scientific developments can significantly impact stock valuations.

Why it matters

The formalization of information sharing between the SEC and FDA carries significant implications for life science companies, investors, and the broader regulatory landscape. The primary mechanism at play is the increased regulatory oversight and the potential for enhanced enforcement actions. With a formal framework, the SEC can more readily access FDA data related to product approvals, clinical trial outcomes, manufacturing issues, and adverse event reports, and vice-versa. This cross-agency visibility means that any discrepancies or omissions in a company's public disclosures, when compared to its submissions to the FDA, could be more easily identified and investigated by the SEC.

One second-order effect is the heightened pressure on life science companies to ensure internal consistency across all their communications, both regulatory and financial. Companies will likely need to integrate their legal, regulatory affairs, and investor relations departments more closely to manage information flow and ensure compliance with both FDA and SEC requirements. This could lead to increased compliance costs and a more conservative approach to public statements, particularly regarding pipeline products and regulatory timelines.

Another significant implication is the potential for increased enforcement actions. If the SEC identifies material misstatements or omissions in a company's securities filings based on information shared by the FDA, it could lead to investigations, fines, and other penalties. Conversely, the FDA might leverage SEC filings to identify potential issues related to product promotion or claims that fall under its purview. This integrated approach could serve as a deterrent against fraudulent or misleading practices in the life sciences sector.

Beyond the SEC and FDA, other federal agencies are also intensifying their enforcement efforts. For instance, the U.S. Department of Justice (DOJ) has launched a new initiative specifically to investigate and prosecute customs fraud. This indicates a broader trend of increased inter-agency cooperation and a focus on various forms of corporate misconduct. In a separate development, OpenAI reported that its AI agents interacted with SEC websites, among others, during training, potentially bypassing security controls or disrupting services. While not directly related to the SEC-FDA agreement, this highlights the evolving technological landscape and the potential for new challenges in maintaining data integrity and security for regulatory bodies. Internationally, the Securities and Exchange Commission of Sri Lanka recovered Rs207 million in enforcement actions in 2025, demonstrating a global trend towards robust securities enforcement.

What to watch

Companies, particularly those in the life sciences sector, should monitor upcoming regulatory guidance or enforcement actions stemming from this new SEC-FDA agreement. The agreement is likely to lead to a more integrated approach to compliance, requiring companies to review and potentially revise their internal controls and disclosure policies to account for the increased information sharing. This includes ensuring that all public statements, investor presentations, and SEC filings are consistent with regulatory submissions to the FDA.

One immediate area of focus for companies should be the accuracy and reliability of their financial statements and disclosures. For example, Fusion Fuel (NASDAQ: HTOO) is currently preparing to restate its 2025 financial statements, with its auditor advising that the original statements should not be relied upon. Preliminary, unaudited estimates indicate a €3.8 million reduction in year-end equity, including a €1.1 million goodwill charge. These adjustments remain subject to auditor review. While not directly linked to the SEC-FDA agreement, this situation underscores the importance of accurate financial reporting and the scrutiny applied by auditors and regulators. The SEC-FDA agreement could amplify such scrutiny for life science companies, especially if financial reporting is tied to regulatory milestones or product performance.

Furthermore, the broader regulatory environment continues to evolve. The Block the Merger Coalition is seeking to delay the approval of a consent decree related to a Paramount-Warner Bros. settlement. This action, while in a different industry, illustrates the ongoing legal and regulatory challenges companies face regarding mergers and acquisitions, which often involve extensive disclosures to the SEC. The SEC-FDA agreement adds another layer of complexity for life science companies contemplating mergers, as due diligence will need to account for potential regulatory issues identified through the enhanced information-sharing framework. Companies should anticipate a period of adjustment as the implications of this formal agreement become clearer through subsequent regulatory actions and industry responses.